Tvardi Therapeutics (NASDAQ:TVRD) Now Covered by Chardan Capital

Analysts at Chardan Capital started coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD) in a report issued on Tuesday, MarketBeat.com reports. The brokerage set a “buy” rating on the stock.

TVRD has been the subject of several other reports. BTIG Research cut their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Lucid Cap Mkts raised shares of Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. Wall Street Zen downgraded Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, October 12th. UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a research report on Wednesday, July 8th. Finally, Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.40.

Tvardi Therapeutics Price Performance

Shares of TVRD opened at $0.97 on Tuesday. The firm has a market cap of $12.94 million, a PE ratio of -0.35 and a beta of 0.38. Tvardi Therapeutics has a 1 year low of $0.93 and a 1 year high of $6.43. The stock’s fifty day moving average price is $1.55 and its two-hundred day moving average price is $2.46.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Sell-side analysts anticipate that Tvardi Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Trading of Tvardi Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at about $34,000. Susquehanna International Group LLP purchased a new position in shares of Tvardi Therapeutics during the second quarter worth about $63,000. Finally, BlackRock Inc. purchased a new position in shares of Tvardi Therapeutics during the second quarter worth about $181,000. Institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.